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Abstract: BG-4 isolated from bitter gourd has been reported for anti-cancer properties. The objective
was to evaluate the anti-inflammatory properties of BG-4 in vitro and in vivo. Comparative study of
the anti-inflammatory properties of BG-4 in vitro and in vivo was conducted on lipopolysaccharide
(LPS)-activated mouse macrophages, and on dextran sodium sulfate (DSS)-induced colitis in mice.
BG-4 reduced the production of pro-inflammatory markers in LPS-activated macrophages. On the
other hand, intraperitoneal administration of BG-4 in DSS-induced colitis led to colon shortening,
elevated neutrophils infiltration and myeloperoxidase activity, presence of blood in the stool, and loss
of body weight, with differential systemic and local effects on pro-inflammatory cytokines in vivo.
The results demonstrated that BG-4 differentially affected inflammation in vitro and in vivo.
Keywords: BG-4; bitter gourd; colitis; inflammation; macrophages
1. Introduction
Inflammatory bowel disease (IBD) is a life-long condition of chronic and relapsing inflammation of
the gastrointestinal tract associated with immune-mediated disorders [1]. It has two major phenotypes:
Crohn’s disease, which can severely affect any part of the bowel, and ulcerative colitis (UC), which
involves damage in the superficial mucosa of the colon, starting always from the anus [1,2]. IBD patients
are at major risk of developing gastrointestinal and extra-intestinal carcinomas, especially those carrying
UC whose probability for developing colitis-associated colorectal cancer (CACC) increases with the
length and severity of inflammatory manifestation [3]. The increasing incidence of UC, especially at a
younger age, has raised a global concern considering the detrimental consequences in terms of quality
of life, economic loss associated with lower productivity and increased medical expenses, and the
imminent risk of development of CACC [2,4]. Hence, alternative ways to manage inflammation are
needed, and plant origin compounds may prevent, ameliorate and alleviate chronic inflammation, and
consequently the risk of IBD and associated diseases.
Momordica charantia, commonly known as bitter gourd, is a member of the Cucurbitaceae family
mainly cultivated in Asia, Africa, and South America [5]. It is traditionally consumed as a vegetable and
with medicinal purposes such as treatment of inflammation, fever, rheumatism, as well as antidiabetic
and anti-helmitic [6]. Several studies have addressed in vitro and/or in vivo effects of the whole edible
parts or extracts with demonstrated anti-oxidant, anti-inflammatory, anti-diabetic, anti-cancer and
metabolic regulatory properties [7–12].
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BG-4 is a novel 4 kDa peptide isolated from bitter gourd seeds with trypsin inhibitory and
in vitro anti-colon cancer and anti-inflammatory properties [13,14]. BG-4 was isolated from the seeds
of Momordica charantia by 70% ethanol extraction. It showed very strong trypsin inhibitory activity
which is at least 8x more potent than purified soybean Kunitz trypsin inhibitor [13]. Moreover,
mass spectrometric analysis showed the following peptide sequence matches: SWPQLVGSTGAAAK,
VGSPVTADFR, GIVARPPAIG and DSDCLAQCICVDGHCG [13]. However, the potential bioactive
properties of BG-4 in animal models remain unexplored. Herein, we made a comparative in vitro and
in vivo anti-inflammatory study of BG-4, by measuring the expression of pro-inflammatory markers
in lipopolysaccharide (LPS)-activated mouse-derived macrophages, and in dextran sodium sulfate
(DSS)-induced colitis in mice. Our results indicate that BG-4 has differential effects in inflammation
within in vitro and in vivo settings.
2. Materials and Methods
2.1. Extraction of BG-4
The 4 kDa peptide BG-4 was extracted from bitter gourd seeds as described previously [13].
2.2. In Vitro Antioxidant Activity of BG-4
The antioxidant capacity of BG-4 was tested via the oxygen radical absorbance capacity assay
(ORAC) as described by Vernaza and coworkers [15] with slight modifications. In brief, 150 µL of
fluorescein solution prepared in phosphate buffer (75 mM, pH 7.4) were plated in a black 96-well
plate. Twenty-five microliters of Trolox standard curve (100–3.125 µM in phosphate buffer), blank or
sample diluted in phosphate buffer were added and incubated at 37 ◦C for 30 min. Then, 25 µL of
2,2′-azobis (2-amidinopropane) dihydrochloride (AAPH) (Sigma-Aldrich, St. Louis, MO, USA) solution
at 41.5 mg/mL in phosphate buffer was added and fluorescence was read at 485 nm/20 nm excitation
and 528 nm/20 nm emission wavelengths for 2 h every min. Each sample and standard curve point
was measured in triplicate and results were expressed as µM of Trolox equivalents/g of BG-4. Radical
scavenging activity was measured by quantifying the inhibition of 2,2-diphenyl-1-picrylhydrazyl
free radical (DPPH•). Briefly, 100 µL of sample and blank were plated in a clear 96-well plate, then
100 µL of 100 µM DPPH• (Sigma-Aldrich, St. Louis, MO, USA) dissolved in methanol were added and
incubated in dark for 30 min. Simultaneously, a combination of sample and methanol, instead DPPH•,
were tested as reference for background signal. Absorbance was read at 517 nm. The absorbance
of methanol reference was subtracted and the percentage of inhibition was calculated against blank.
Results are presented as percentage of scavenging rate of DPPH•.
2.3. Measurement of Pro-Inflammatory Markers In Vitro
Murine RAW 264.7 macrophages were cultured in DMEM supplemented with 10% heat-inactivated
fetal bovine serum (Life Tech, Carlsbad, CA, USA) and 1% penicillin/streptomycin at 37 ◦C in a
humidified 5% CO2 incubator. Cells were seeded at 2 × 105 cells/well in 6-well plates in 2 mL media,
or 5 × 103 cells/well in 96-well plates in 200 µL media and allowed to attach overnight. Cells were
treated with BG-4 (0–500 µg/mL) for 8 h and stimulated with LPS (1 µg/mL) for 16 h. After which,
supernatant was collected for TNF-α and IL-6 measurement via ELISA following the manufacturer’s
protocol (BioLegend, San Diego, CA) and nitric oxide (NO) production by Griess reagent assay.
Whole cell lysates were collected for immunoblotting of inducible nitric oxidase synthase (iNOS) and
cyclooxygenase-2 (COX-2) (ProteinTech, Chicago, IL, USA) by chemiluminescence following standard
protocol. Cell viability was tested by MTS assay following the manufacturer’s protocol (Promega,
Madison, WI, USA).
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2.4. Dosage Information and In Vivo Experimental Procedure
The BG-4 dose used in the animal study (15 mg/kg body weight (bw)) is equivalent to the
optimum concentration (375 µg/mL) of BG-4 in vitro producing significantly decreased expression of
pro-inflammatory markers without affecting cell viability. This translation assumes an average mouse
weight of 25 g and circulating blood of 1 mL. This will be equivalent to a daily intake of two 500 mg
capsules as a dietary supplement for a 70-kg person. The protocol for the animal experiment was
approved by the Institutional Animal Care and Use Committee of the University of Tennessee Knoxville
(Approval Protocol #2591-0418) and followed guidelines of the National Institutes of Health guide for
the care and use of Laboratory Animals (NIH Publications No. 8023, revised 1978). Twenty-two male
C57BL/6 7-week old mice (Jackson Laboratories, Harbor, ME, USA) were randomized and housed in
pairs in standard mouse cages with water and food provided ad libitum, under standard controlled
conditions (23 ± 2 ◦C, 30–70% relative humidity with 12 h light and 12 h dark cycle). Mice were
randomly divided into three groups and treated as follows: control group (CG, n = 6), DSS-treated group
(DSS, n = 8), and DSS + BG-4-treated group (BG-4, n = 8). Mice in CG were administered with normal
drinking water, while DSS and BG-4 groups received drinking water with 3% DSS (MW = 36–50 kDa,
MP Biomedicals, Santa Ana, CA) to induce colitis. Two stages of DSS administration were performed
allowing a recovery period in between, in order to simulate the periods of relapse and remission that
IBD patients experience [16]. Daily intraperitoneal injection (IP) of 100 µL sterile water was performed
over CG and DSS groups, while BG-4 received IP of 15 mg BG-4/kg bw dissolved in 100 µL sterile
water. Food intake and body weight were recorded daily. Presence of visible blood (in stool or anus),
as well as stool consistency, were monitored and scored daily. Stool samples were collected from the
cages every three days to evaluate the presence of occult blood via quantification of hemoglobin in
feces. At day 15, mice were anesthetized with isoflurane, blood collected by cardiac puncture, followed
by cervical dislocation. Colon was removed, washed with PBS, length measured and cut longitudinally
into two pieces: one for hematoxylin and eosin (H&E) staining, and the other frozen in liquid nitrogen
for biochemical analysis.
2.5. Myeloperoxidase Assay in the Colon
Neutrophils infiltration was assessed by measuring myeloperoxidase (MPO) activity in colonic
extracts as reported previously [17] with slight modifications. Colonic extracts were obtained by beads
homogenization of 50 mg of colon samples with 1 mL buffer (5 g of hexadecyltrimethylammonium in
1 L of 50 mM potassium phosphate buffer at pH 6.0), followed by centrifugation at 20,000× g for 15 min
at 4 ◦C. Supernatant was collected and further centrifuged to ensure total precipitation of solid tissue.
Ten µL of supernatant was plated in triplicate in a 96-well plate and combined with 200 µL freshly
prepared o-dianisidine solution (16.7 mg of o-dianisidine, 90 mL of deionized water and 10 mL of
potassium phosphate buffer, combined with 50 µL of 1.2% H2O2). Absorbance at 450 nm was recorded
every 30 s for 5 min. MPO activity was calculated as the amount needed to degrade 1 µmol H2O2/min
at 21–22 ◦C per mg protein in the colonic extract.
2.6. Measurement of Hemoglobin Content in the Feces
Presence of occult blood in the feces was assessed by measuring hemoglobin content [18,19].
Twenty mg of freeze-dried pulverized samples were vortexed with 100 µL dH2O, and boiled for 10 min.
Six hundred microliters of 30% acetic acid was added, vortexed for 2 min, then 900 µL of ethyl acetate
was added, and organic layer was collected in a separate microcentrifuge tube after centrifugation at
2000× g for 3 min. In a quartz cuvette, equal parts of the organic phase and TMB solution (14.4 mg of
3,3′,5,5′-tetramethylbenzidine in 100 mL mixture of glacial acetic acid/dH2O/ethanol 20/30/50) were
mixed and the reaction was started by adding the same amount of 3% H2O2. The absorbance was
recorded at 660 nm at 30 s, 60 s, and 90 s. Hemoglobin content was calculated as the average for
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the three time points per mg of feces using bovine hemoglobin (Alfa Aesar, Ward Hill, MA, USA)
standard curve.
2.7. Measurement of Cytokines by ELISA
Supernatants of treated macrophages, as well as blood serum and colonic extracts, were used to
measure the expression of pro-inflammatory cytokines using ELISA kits according to manufacturer
instructions (BioLegend, San Diego, CA, USA).
2.8. Statistical Analysis
All experiments were performed in triplicate. Results were reported as mean ± SD or SE.
Analysis of variance (ANOVA) and Tukey’s test were used to establish significant differences (p < 0.05)
and t-student for comparison of two samples or groups, using Statgraphics Centurion ® software
(Statgraphics Inc, The Plains, VA, USA).
3. Results and Discussion
3.1. BG-4 Exert Antioxidant and Antiradical Activity
Antioxidant capacity of BG-4 was estimated as 4.72 ± 0.41 µM of Trolox Equivalent per gram,
being comparably higher to that reported for protocatechuic acid and protocatechuates (<3 µM of
Trolox Equivalent/g) [20]. The ability of BG-4 to convert DPPH radical into it picrylhydrazine form
increase about 1.6 times when doubling the concentration, as it can be seen in Figure 1, exerting up to
26% inhibition at a concentration of 0.5 mg/mL of BG-4.
Antioxidants 2019, 8, x FOR PEER REVIEW 4 of 11 
Supernatants of treated acrophages, as well as blood seru  and colonic extracts, were used to 
easure the expression of pro-infla atory cytokines using ELISA kits according to anufacturer 
instructions (BioLegend, San Diego, CA, USA). 
. .  l i  
ll ex eri t  ere perfor e  in triplicate. s lts r         
nalysis of variance (ANOVA) and Tukey’s est were used to establ sh significant diff rences (p < 
0.05) and t-student for comparison of two samples or groups, using Statgraphics Centurion ® soft are 
(Statgraphics Inc, The Plains, A, USA). 
. s lts  isc ssi  
3.1. BG-4 Exert Antioxidant and Antiradical Activity 
Antioxidant capacity of BG-4 was estimated as 4.72 ± 0.41 μM of Trolox Equivalent per gram, 
being comparably higher to that reported for protocatechuic acid and protocatechuates (<3 μM of 
Trolox Equivalent/g) [20]. The ability of BG-4 to convert DPPH radical into it picrylhydrazine form 
increase about 1.6 times when doubling the concentration, as it can be seen in Figure 1, exerting up 
to 26% inhibition at a concentration of 0.5 mg/mL of BG-4. 
 
Figure 1. Radical scavenging activity of BG-4 calculated as % of inhibition of DPPH free radical for 
different concentrations. Results are presented as mean ± SD. 
3.2. BG-4 Decreased Expression of Pro-Inflammatory Markers In Vitro 
Macrophages are part of the first line of defense against injury, mediating the innate non-specific 
immune response via inflammation, and playing an important role not only in host defense but in 
tissue homeostasis, repair, and pathology development including IBD [21,22]. RAW 264.7 mouse 
derived macrophages have been widely used as in vitro model to study modulatory effects of several 
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effector molecules such as pro-inflammatory cytokines (IL-6, TNF-α, IL-1β) and nitric oxide (NO) 
that act as mediators of inflammation during the host immune response [6]. The destruction of 
normal and healthy tissue as a result of chronic inflammatory condition can lead to IBD, rheumatoid 
arthritis and multiple sclerosis [26], hence reducing the level of these pro-inflammatory secreted 
molecules can lead to management and alleviation of these diseases. BG-4 dose-dependently reduced 
the production of NO (Figure 2B) and IL-6 (Figure 2C) in LPS-activated RAW 264.7 macrophages. 
Moreover, the expression of iNOS and COX-2 (Figure 2D) was reduced by BG-4. 
Figure 1. Radical scavenging activity of BG-4 calculated as % of inhibition of DPPH free radical for
different concentrations. Results are presented as me n ± SD.
3.2. BG-4 Decreased Expression of Pro-Inflammatory Markers In Vitro
Macrophages are art of the first line of defense against injury, mediating the innate non-specific
immune response via inflammation, and playing an important role not only in host defense but in
tissue homeostasis, repair, and pathology development including IBD [21,22]. RAW 264.7 mouse
derived macrophages have been widely used as in vitro model to study modulatory effects of several
compounds using LPS for activation [23–25]. Treatment with BG-4 at concentrations up to 375 µg/mL
did not affect the viability of macrophages (Figure 2A). It is known that LPS can activate NF-κB which
acts as a master regulator of the inflammatory response by promoting the release of signaling and
effector molecules such as pro-inflammatory cytokines (IL-6, TNF-α, IL-1β) and nitric oxide (NO) that
act as mediators of inflammation during the host immune response [6]. The destruction of normal
and healthy tissue as a result of chronic inflammatory condition can lead to IBD, rheumatoid arthritis
and multiple sclerosis [26], hence reducing the level of these pro-inflammatory secreted molecules can
lead to management and alleviation of these diseases. BG-4 dose-dependently reduced the production
of NO (Figure 2B) and IL-6 (Figure 2C) in LPS-activated RAW 264.7 macrophages. Moreover, the
expression of iNOS and COX-2 (Figure 2D) was reduced by BG-4.
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Figure 2. Effect of BG-4 on viability of activated lipopolysaccharide (LPS+) and non-activated (LPS-)
macrophages (A), NO production (B), cytokine production (C), and iNOS and COX-2 expression (D),
in vitro. Results are presented as mean ± SD for (A–C) and mean ± SE for (D). Different letters indicate
significant differences (p < 0.05) among treatments.
These results suggest that the mechanistic effect of BG-4 had a major impact on molecules
particularly involved in the pathway associated with the specific expression of iNOS and IL-6, and
consequently over their downstream products, but affected in a lower extent the expression of
COX-2 and TNF-α. Hence, we selected 375 µg/mL concentration to study the ability of BG-4 to
ameliorate DSS-induced colitis in mice with a translation of IP administration of BG-4 at 15 mg/kg bw
assuming an average mouse weight of 25 g and a circulating blood volume of one milliliter. Two
stages of DSS administration were performed in order to induce damage to the epithelial barrier in
the colon to simulate colitis, allowing a period of recovery in between as presented in Figure 3A.
This experimental design mimics the periods of remission and relapse that IBD pati nts usually
experience [16]. BG-4 dministration started at three days post DSS to mimic ingestion of BG-4 as a
supple ent for am liorating established IBD ( rsus preventio ) in um n as there are no known risk
factors to IBD. Hence, it is highly likely that dietary supp ement will be consumed for management
and not for the prevention of IBD.
3.3. IP Administration of BG-4 did not Alleviate Indicat i ivo
The damage in the col nic mucosa that occ r i l r ti e colitis results in different symptoms
and indicators such as diarrhea, presence of blood in the stool, increased frequency of bowel movements,
mucus discharge, abdominal pain, weight loss, bloody diarrhea, and rectal bleeding irritation and
fissures [27]. Daily monitoring of body weight, presence of visible blood and stool consistency were
performed, in order to establish variation of external indicators of the disease. CG maintained a
constant incremental increase in weight while the DSS group presented a significant decrease starting
at day five, and minimum trough at day seven, with a 6% loss of original weight. BG-4 administration
in DSS-treated mice showed a continued loss in weight until day nine and in days 14 and 15 with a
10% decrease in body weight at euthanasia as shown in Figure 3A. For CG, no visible blood in the stool
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or anus and normal stool consistency were observed with a disease score of zero (Figure 3B) neither
DSS nor BG-4 groups presented watery or bloody diarrhea, but changed in stool consistency, becoming
much softer in comparison to CG group and BG-4 administration led to stool softening earlier than
DSS group as shown in Figure 3B. Presence of blood in stool was observed for DSS and BG-4 groups
mostly between days 3–6 and 10–14, but the frequency of mice presenting blood in the anus was higher
for BG-4 than for DSS group as presented in Figure 3C.
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Figure 3. Animal study design and effect of BG-4 treatment over relative weight (A), stool consistency
(B), and presence of visible blood (C) on dextran sodium sulfate (DSS)-induced colitis in mice. Scores
for stool consistency and presence of visible blood for CG were 0 for every observation. Results are
presented as mean ± SE. Different letters indicate significant differences (p < 0.05) among treatments.
Overall, external indicators of the disease suggest that DSS administration induced colitis with
a mild grade of severity in this study. Since diarrhea or reduction in food intake were not observed,
loss of body weight might be due to an increased frequency in bowel movements with a softened
stool consistency and presence of blood, that upon re oval of DSS was compensated by food intake,
allowing partial or total recovery of the animals. However, the lower extent of recovery for BG-4 group,
in addition to the higher fr quency of animals with rectal bleeding may in icate that IP adminis ration
of BG-4 aggravated symptoms of the disease.
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3.4. IP Administration of BG-4 Aggravated DSS-Induced Colitis in Mice
Colon shortening has been reported for several studies as an outcome of colitis in animal
models [6,28–30]. BG-4 group presented a significant reduction in average colon length of about 2 cm
in comparison with CG as shown in Figure 4A. H&E staining allows a comparison of the effects of DSS
challenge and BG-4 treatment over the internal structure of colonic tissue. Micrographs of stained
colonic tissue for the three groups show that animals under DSS-induced colitis exhibited immune cells
infiltration (black arrows) in the lamina propria, and a distortion of crypts architecture (white arrows)
accompanied by the loss of goblet cells (Figure 4B). In the case of BG-4, infiltration was extended to the
muscularis region and to form crypt abscesses and reach the glandular lumen of the crypts forming
abscesses as shown in Figure 4B.
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Figure 4. Colon length (A), H&E staining of colonic tissue (B), MPO activity (C), and fecal hemoglobin
(D) on DSS-induced colitis in mice. Results are presented as mean ± SD (A) and (C) or SE (D). Different
letters and * indicate significant differences (p < 0.05) among treatments. Immune cells infiltration and
distortion of the crypt architecture are indicated by black and white arrows, respectively.
MPO is a peroxidase enzyme that plays an important role during infections by modulating the
production of hypochlorous acid and other non-selective reactive species that mediate pathogens
killing, and can induce host tissue damage by promoting inflammation [31]. It is mainly present in
specialized granules of neutrophils hence elevated MPO levels and neutrophil infiltration have been
correlated to inflammatory autoimmune disorders [32]. DSS and BG-4 groups exhibited an MPO
activity four and 14 times higher, respectively, than CG (Figure 4C), corroborating observations in H&E
staining micrographs where a higher infiltration of immune cells was detected for both groups with
elevated severity upon BG-4 treatment.
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Quantification of hemoglobin in collected feces was used to estimate fecal occult blood. Figure 4D
indicates the presence of hemoglobin in feces for BG-4 and DSS groups followed the same trend as
loss in weight. At the end of the study, the presence of hemoglobin in feces from BG-4 group was
significantly higher than in DSS group, being consistent with the observations and scoring for the
visual presence of blood in stool or rectum presented in Figure 3B,C.
3.5. IP Administration of BG-4 Exerted a Differential Systemic and Localized Effect in Pro-Inflammatory
Cytokines In Vivo
Cytokines are signaling proteins that contribute to the modulation of the immune and inflammatory
response during tissue damage and repair. The levels of pro-inflammatory cytokines IL-6, TNF-α,
and IL-1β in colonic extracts (A) and in serum (B) are presented in Figure 5. No significant effect was
observed upon DSS challenge and/or BG-4 treatment over the expression of IL-6 and TNF-α in colonic
extracts, but both compounds were upregulated in serum in the DSS group and attenuated under BG-4
treatment (Figure 5A,B). IL-1β, in contrast, was upregulated in the DSS group and attenuated in the
BG-4 group in colonic extracts but remained high in serum (Figure 5A,B). These results suggest that
DSS and BG-4 were capable to exert a systemic (in circulating blood) but not localized (in colonic tissue)
effect. A recent study has demonstrated dysregulation of pro-inflammatory cytokines in DSS-induced
colitis mouse model with similar differential outcomes at the serum and colonic level observed in
our study [33]. The particular differences in the systemic and localized effect over cytokines seem to
indicate that IP injection allowed BG-4 to reach blood circulation, as expected for the high bioavailability
reported for this administration route but post the question if the appropriate concentration was,
in fact, capable to reach the intestinal barrier, where the tissue damage was induced via DSS and the
inflammatory response was concentrated.
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Our results showed that BG-4 exerted a differential effect over inflammation in vitro and in vivo.
In LPS-stimulated macrophages, treatment with BG-4 showed a dose-dependent reduction of NO,
IL-6, COX-2, and iNOS, suggesting 375 µg/mL as an optimal concentration for significant reduction of
inflammatory markers. However, IP administration of BG-4 in a DSS-induced colitis mouse model,
aggravated disease symptoms when compared with untreated mice, accompanied by the dysregulation
of pro-inflammatory cytokines. The systemic circulation of BG-4 due to IP administration involved a
possible effect over other immune and epithelial cells that can be more or less sensitive, in terms of
cytotoxicity [34] and alteration of signaling and regulatory pathways, than the tested macrophages. For
instance, it has been recently demonstrated the induction of NO metabolism in enterocytes alleviates
colitis and CACC [29], suggesting a controversial role of NO in the regulation of the inflammatory
response associated with its origin. According to this perspective, suppression of NO production
exerted by BG-4 could result in a counteracting effect by simultaneously suppressing NO production
on macrophages and enterocytes.
The outcomes observed in vivo under BG-4 treatment suggest that the mechanistic effect by which
BG-4 suppresses NO production may be associated with enterocyte than macrophages. Under this
circumstance, the reduced expression of NO by the enterocyte allows neutrophils infiltration, generation
of cytotoxic compounds by MPO, tissue damage, and a consequently increased inflammatory response.
One strength of our study is the first report on the comparative anti-inflammatory properties of BG-4
peptide from Momordica charantia using both in vitro and in vivo models. In addition, both mouse cell
line and mouse model of colitis were utilized in the study. On the other hand, the observed contrasting
result of in vitro and in vivo models on the anti-inflammatory effect of BG-4 is a potential weakness.
The intraperitoneal injection of BG-4 may have resulted in the toxic effect of BG-4 in mouse model
resulting in its pro-inflammatory effect which is contradictory in the observed anti-inflammatory effect
in vitro. Hence the next step on the potential application of BG-4 for management of inflammatory
diseases must be observed via oral route to determine if it can be used as a dietary supplement to
mitigate diseases such as colitis.
4. Conclusions
In RAW 264.7 macrophages, BG-4 reduced the production of pro-inflammatory molecules NO,
IL-6 and TNF-α as well as the expression of COX-2 and iNOS. On the other hand, in DSS-induced
colitis mouse model intraperitoneal administration of BG-4 led to diarrhea, blood in stool and loss in
weight. Our results demonstrated that IP administration of BG-4 in DSS-induced colitis mouse model
led to a worsened outcome of the disease, in contrast to the reduction of the pro-inflammatory markers
observed in vitro. BG-4 dose and route of administration must be further studied to realize the role of
BG-4 in ameliorating IBD.
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